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Abstract
Renal ischemia-reperfusion (IR) injury (IRI) is a common and important trigger of acute renal injury (AKI). It is inevitably
linked to transplantation. Involving both, the innate and the adaptive immune response, IRI causes subsequent sterile
inflammation. Attraction to and transmigration of immune cells into the interstitium is associated with increased vascular
permeability and loss of endothelial and tubular epithelial cell integrity. Considering the important role of cytoskeletal
reorganization, mainly regulated by RhoGTPases, in the development of IRI we hypothesized that a preventive, selective
inhibition of the Rho effector Rho-associated coiled coil containing protein kinase (ROCK) by hydroxyfasudil may improve
renal IRI outcome. Using an IRI-based animal model of AKI in male Sprague Dawley rats, animals treated with hydroxyfasudil
showed reduced proteinuria and polyuria as well as increased urine osmolarity when compared with sham-treated animals.
In addition, renal perfusion (as assessed by 18F-fluoride Positron Emission Tomography (PET)), creatinine- and urea-
clearances improved significantly. Moreover, endothelial leakage and renal inflammation was significantly reduced as
determined by histology, 18F-fluordesoxyglucose-microautoradiography, Evans Blue, and real-time PCR analysis. We
conclude from our study that ROCK-inhibition by hydroxyfasudil significantly improves kidney function in a rat model of
acute renal IRI and is therefore a potential new therapeutic option in humans.
Citation: Kentrup D, Reuter S, Schno¨ckel U, Grabner A, Edemir B, et al. (2011) Hydroxyfasudil-Mediated Inhibition of ROCK1 and ROCK2 Improves Kidney Function
in Rat Renal Acute Ischemia-Reperfusion Injury. PLoS ONE 6(10): e26419. doi:10.1371/journal.pone.0026419
Editor: Holger K. Eltzschig, University of Colorado Denver, United States of America
Received May 5, 2011; Accepted September 26, 2011; Published October 21, 2011
Copyright:  2011 Kentrup et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Innovative Medical Research (IMF, Project I-BU¨ 9844000) and the Interdisciplinary Centre for Clinicial Research (IZKF,
Core Unit SmAP) of the Medical Faculty Mu¨nster, Germany, and the German Research Foundation (DFG, SFB656C7). The authors acknowledge support by Open
Access Publication Fund of University of Muenster. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: buessema@hotmail.com
. These authors contributed equally to this work
Introduction
AKI is a critical clinical condition associated with a high degree
of morbidity and mortality despite best supportive care. However,
at present, no effective treatment improving outcome is available.
IRI is one of the main causes of AKI. It occurs in a broad
spectrum of clinical settings including (transplantation) surgery,
trauma, dehydration or sepsis leading to renal hypoperfusion,
acute tubular necrosis (ATN), and functional disturbances -
namely AKI. In renal transplantation it is a well known risk
factor for delayed graft function, which prolongs hospitalization,
increases costs, and needs a greater complexity of immunosup-
pressive drug management. Because IRI affects the kidney by
reducing the number of nephrons and increases the risk of acute
rejection episodes, it might cause a reduced graft survival.
Among the complex mechanisms involved in IRI, recent
interest has focused on detailed studies of immune cells involved
in the post-ischemic processes, thereby identifying inflammation as
a key mediator of IRI. Even though the data regarding the cell
types typically involved varies (e.g. due to the models used [1,2] or
due to non specific detection methods, e.g. myeloperoxidase,
naphthol chloroacetate esterase, or HIS-48 staining [3]) it is well
known that the increased influx of neutrophiles, T- and B-
lymphocytes as well as macrophages/monocytes significantly
contributes to the pathogenesis of AKI [4]. Neutrophiles and
other attracted leukocytes adhere to endothelial cells using specific
adhesion molecules such as intercellular adhesion molecule 1
(Icam1) and vascular cell adhesion molecule 1 (Vcam1) followed
by transendothelial migration [5–9], often accompanied by plasma
fluid and protein leakage [10]. In addition, activated leukocytes
produce a variety of hyperpermeability factors, including cyto-
kines, oxidants, proteases, lipid metabolites, and leukotrienes
which directly or indirectly interact with the endothelium.
Recently, it has been shown that Rho effectors Rho-associated,
coiled-coil containing protein kinases (ROCK) and their associated
signaling pathways play pivotal roles in the development of
(experimental) renal diseases [11–14]. ROCKs are protein serine/
threonine kinases belonging to the AGC (PKA/PKG/PKC)
family. They were the first effectors of Rho discovered [15–
17]. To date, two ROCK isoforms, ROCK1 (ROKb [18],
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p160ROCK [15]) and ROCK2 (ROKa [16], Rho kinase [17])
have been described. ROCKs are ubiquitously expressed [18,19]
and they phosphorylate various substrates [20–24]. Their
involvement in the regulation of cellular motility, migration,
adhesion, and transmigration is hereby of special interest. Notably,
in leukocytes ROCKs are essential mediators for these processes
[25–32]. Considering the important role of cytoskeletal reorgani-
sation, mainly regulated by RhoGTPases, in the development of
IRI-related AKI, we hypothesized that ROCK blockade may
improve renal IRI outcome. Considering that leukocyte recruit-
ment into the kidney is rather detrimental in the first stages of IRI,
while providing possible beneficial effects in the later IRI stages,
we chose a preventive approach using transitory ROCK-inhibition
before and early in IRI [33].
Thus, using an animal model of renal IRI, we aimed to
investigate whether ROCK-inhibition by hydroxyfasudil (HF), a
specific inhibitor of ROCK1 and ROCK2 with an estimated half
life of more than 5 hours, affects adhesion, migration, and
transmigration of immune cells thereby reducing early, post IR
leukocyte-endothelial interactions, endothelial leakage, post-ische-
mic inflammation, and kidney damage.
Materials and Methods
Animal models
Male Sprague Dawley (SD) rats (270–330 g, Charles River,
Sulzfeld, Germany) with free access to food (standard rat chow,
Altromin, Lage, Germany) and tap water were used. Experiments
were approved by a governmental-committee on animal welfare
(Landesamt fu¨r Natur, Umwelt und Verbraucherschutz Nordr-
hein-Westfalen, Permit # 8.87-50.10.36.09.020) and were per-
formed in accordance with national animal protection guidelines.
Surgeries were performed under anaesthesia with ketamine
100 mg/kg body weight (BW) intra peritoneal (i.p.) and xylazine
5 mg/kg BW i.p. (CEVA Tiergesundheit, Du¨sseldorf, Germany).
Further doses of ketamine were injected as needed.
IRI model
Before induction of IRI, rats underwent right nephrectomy. 7
days later, IRI was induced by clamping the left renal artery for
45 min (in a modification as published before [34]). Briefly,
kidneys and vessels were approached through an abdominal
midline incision. The left renal artery and vein were dissected free
from connective tissue and from each other. All visible renal
nerves were carefully detached from the vessels. Blood-flow
through the left renal artery was interrupted by a vessel clip for
warm ischemia. After 45 min of ischemia, the vessel clip was
removed. The returning of original surface colour of the kidneys
was confirmed visually, and the abdomen was closed in layers.
Rats were randomized into two groups: one hour before the
ischemia procedure rats received either 10 mg/kg HF (i.p.) or
vehicle solution (isotonic NaCl, i.p.). In the following reperfusion
phase animals were housed for 1–4 days in metabolic cages; blood
and urine samples were taken daily for analysis. On POD0, POD1
or POD4, respectively, kidneys were recovered for analyses.
For assessment of renal perfusion by PET IRI was
induced as described above except of performance of the
uninephrectomy. This variant was chosen because herein the
native reference kidney and the contralateral kidney with IRI can
be directly compared in the same animal.
Blood-pressure
Mean systolic and diastolic blood-pressures were measured in
conscious rats by use of a non-invasive, volume pressure recording
technique (CODA, Kent Scientific Corporation, Connecticut) as
published before [35]. First, animals were acclimatized to the
system through daily training for 1 week prior uninephrectomy,
followed by additional training after the animals had recovered.
Final measurements were carried out immediately before the
ischemia procedure (starting 30 min after the animals received
either 10 mg/kg HF (i.p.) or vehicle solution (isotonic NaCl, i.p.)
and ending 10 min before surgery). Each animal underwent a
complete measurement cycle containing 25 consecutive single
measurements from which means were calculated. All animals
were trained by the same researcher at the same time of the day to
minimize stress and the effect of biological rhythms.
Image acquisition -PET
18F-FDG and 18F-fluoride were produced in a clinical routine
setup on site using an RDS 111 cyclotron (CTI, Knoxville, TE,
USA). PET scans were performed with the high-resolution multi-
wire chamber-based animal PET camera quadHIDAC (Oxford
Positron Systems Ltd, Oxford, UK) [36]. Renal perfusion was
assessed by 18F-fluoride PET. The perfusion index was calculated in
a modification according to Hilson et al. as the ratio between the
area under the arterial curve during the first 30 seconds*100 after
tracer injection and the area under the renal curve [37].
18F-fluoride scans were performed at baseline, immediately after
ischemia (POD0: briefly, the vascular clamp was recovered and
the abdomen closed in layers with stitches. Thereafter, the
operation tray with the rat was transferred to the PET. These
procedures took approximately 10-15 min), and on POD4 from a
dynamic whole body acquisition of 60 min length (to get
additional information about renal fluoride clearance as a marker
of renal function and about split renal function [34]) after tail vein
injection of 15 MBq 18F-fluoride in 100 ml 0.9% NaCl. Thereafter,
the catheter was purged with an additional 900 ml 0.9% NaCl
solution. Acquisition started immediately after 18F-fluoride
injection. During acquisition, rats were anaesthetized with
oxygen/isoflurane inhalation (2% isoflurane, 0.7 l/min oxygen)
and body temperature was maintained at physiological values by a
heating pad.
18F-FDG-autoradiography
Autoradiography (m-imager, Biospace Measures, Paris, France)
was performed as published before [38,39] on POD4. In short,
3 hours after i.v. injection of 30 MBq 18F-FDG in 100 ml 0.9%
NaCl solution in a tail vein, kidneys were snap-frozen, sliced into
10 mm thick cryosections and activity was measured in a mid-
coronary renal slice for 3 h.
Evans Blue
Endothelial permeability was determined by assessing tissue
concentration of Evans Blue (EB, Santa Cruz Biotechnology,
Heidelberg, Germany). Complementary to the surgery animals
received 30 mg/kg EB by tail vein injection at initiation of the
reperfusion phase. After 30 min kidneys were perfused with 100 ml
of isotonic NaCl, excised, shredded, and dehydrated. Samples were
homogenized in formamide whereby total volume was adjusted to a
20x equivalent of sample dry weight, followed by 24 h incubation at
55uC. Supernatant was separated by centrifugation at 13.000 g for
30 min and EB concentration in the supernatant was quantified
spectrophotometrically by measuring absorbances at 620 nm, as
well as at 740 nm for the correction of contamination by heme
pigments by applying a microplate reader (InfiniteH F200, TECAN
Deutschland GmbH, Crailsheim, Germany). Total concentration of
EB was determined from generated EB standard curves absorbanc-
es, and expressed as mg/ml.
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Histology
Kidneys were recovered either on POD1 or POD4. The renal
capsule was removed. Cross-sections were obtained, fixed in 4%
buffered paraformaldehyde and embedded in paraffin. 5-mm-
thick slices were then deparaffinized, rehydrated and stained with
periodic acid Schiff (PAS). Digitalized pictures were taken with a
microscope (Axiovert 100, Carl Zeiss AG, Oberkochen, Ger-
many) equipped with a digital camera (Axiocam MRc, Carl
Zeiss AG) using the AxionVisonLE Release 4.7.1 software (Carl
Zeiss AG).
Immunohistochemistry
Small pieces of kidney tissue were fixed in 4% formaldehyde in
PBS for 12 h and embedded in paraffin. After deparaffinisation
and rehydration with Clear Rite and descending ethanol series, 3-
mm-thick sections were blocked with BSA 10% and immuno-
stained employing the ABC method with antibodies against
Mmp2 and Mmp9, respectively. Reaction products were visual-
ized by DAB reaction. After counterstaining with haemalaun,
images were acquired using an Axio Zeiss light microscope
(Axiovert 100, Carl Zeiss AG, Oberkochen, Germany) equipped
with a digital camera (Axiocam MRc, Carl Zeiss AG) using the
AxionVisonLE Release 4.7.1 software (Carl Zeiss AG). Control
stainings were performed without using primary antibody.
Western Blotting Analysis
Kidneys of HF- and sham-treated animals were recovered 1 h
after the animals had received their corresponding treatment.
Subsequently, kidneys were lysed and submitted to immunoblotting
analysis by using specific antibodies against phospho-MYPT1
(Thr853) (Cell Signaling) and GAPDH (Cell Signaling).
Clinical Chemistry
Blood and urine samples were analyzed for electrolytes (ISE),
creatinine (enzymatic assay; Creatinine-Pap, Roche Diagnostics,
Mannheim, Germany) and blood urea nitrogen (BUN, urease-
GLDH method) on a Roche Diagnostic analyzer (Modular P,
Roche Diagnostics). Additionally, urine protein concentration
(Bradford Blue; BioRad Laboratories, Germany) and osmolarity
(Halbmikro-Osmometer, Knauer, Berlin, Germany) were mea-
sured.
Gene expression analysis
Tissue samples were taken on POD1 or POD4, preserved in
RNAlater RNA Stabilisation Reagent (Qiagen, Hilden, Germany)
and stored at 220uC. Gene expressions were analyzed by real-
time PCR using the SYBR Green PCR Master Mix [40] (Applied
Biosystems, Darmstadt, Germany) with the ABI PRISM 7900
Sequence Detection System. GAPDH was used as housekeeping
gene. Relative gene expression values were evaluated with the
2-DDCt method as described by Livak et al.. Primers are listed in
table 1.
Statistics
Statistical analyses were performed using GraphPad Prism
version 4.0 (GraphPad Sofware, La Jolla, CA, USA). Values are
expressed as mean 6 SEM. Comparison among groups was
performed by one-way ANOVA along with post-hoc Tukey test,
Table 1. Primer sequences used for gene expression analysis by real-time PCR and their corresponding genes.
Gene
(official symbol & name) Primer Sequence
Forward (59-39) Reverse (59-39)
CD4 (CD4 molecule) TGTGTCAGGTGCCGGCACCAACAG GTGGGGCCCAGGCCTCATATG
CD8a (CD8a molecule) AGGGAATGGGATTGGGCTTCGC CTCTGAAGGTCTGGGCTTGAC
CD80 (CD80 molecule) CGTTTGCCTGGGCAGGATCTG GCTGCTTCCACAGGCCCTATG
CD86 (CD86 molecule) GCTCTCAGATGCTGTTCCTGTG ATAGTGTTCGTACAGAACCGAC
Ceacam1 (CD66a, carcinoembryonic antigen-related cell adhesion molecule 1) GTGAAGCCCGGAACCCAGCG GTCTGCATGGCAGGAGAGGTTG
Fcnb (ficolin B) GAACCAATGAGCTGCGGGTGG GTTTTGGGAAGTCAGGGAGTCAC
Foxp3 (forkhead box P3) GTGGTGCAGTCTCTGGAGCAGC CAGGAGCTCTTGTCCACTGAGGC
Gapdh (glyceraldehyde-3-phosphate dehydrogenase) CATCAACGACCCCTTCATT ACTCCACGACATACTCAGCAC
Icam1 (intercellular adhesion molecule 1) CGGGAGATGAATGGTACC GCGGTAATAGGTGTAAATGG
Ifng (interferon gamma) GTCATCGAATCGCACCTGATC GGCTAGATTCTGGTGACAGCTG
Il2ra (CD25, interleukin 2 receptor, alpha) GCAGTGGCCAGCTGCATCTTC CTAGCTTGCTAGATGGTTCTTCTGC
Kim1 (Havcr1, kidney injury molecule1) GAGCACCGTGGTTGTCACCAGG GTAGATGTTGTCTTCAGCTCGGG
Mmp2 (matrix metalloproteinase 2) GCTCAGATCCGTGGTGAGATCTTC TTTCCGGGAGCTCAGGCCAGAATG
Mmp7 (matrix metalloproteinase 7) GCCACTCATGAACTTGGCCAC CTGCATCTATCACAGCTTGTTCC
Mmp8 (matrix metalloproteinase 8) ATCTGGAGTGTGCCATCAACCC CCGGCCTGGTTGAAAGGCATG
Mmp9 (matrix metalloproteinase 9) AAGGCCATTCGTTCACCGCGC CACGTCTCGCGGCAAGTCTTC
Ms4a1 (CD20, membrane-spanning 4-domains, subfamily A, member 1) CTGTGGGGAGGCATTATGTAC CCAGAAATGGCAGCAAAGAGGC
Ncam1 (CD56, neural cell adhesion molecule 1) CTGACATGTGAAGCCTCCGGAG CTCTTGCTTCTCTGGTCGAGTC
Tnf (tumor necrosis factor) AAGTTCCCAAATGGGCTCCCTC GCTCCTCCGCTTGGTGGTTTG
Tnfsf15 (tumor necrosis factor (ligand) superfamily, member 15) GTGACAGAAGAGAGGTCTGCC GGTTCTTGGTGAAGGCCATCC
Vcam1 (vascular cell adhesion molecule 1) CTGTTTGCAGTCTCTCAAGC GCTTCAAAGCCTTCTTTGTGC
doi:10.1371/journal.pone.0026419.t001
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whereas a significance level of p,0.05 was defined as statistically
significant.
Results
ROCK-inhibition improves post-ischemic renal function
To estimate renal function, blood and urine samples were
analyzed at baseline, as well as after IRI on POD1 and 4. Before
starting the interventions, parameters did not differ between
groups (Table 2). One week after uninephrectomy no significant
differences to healthy animals were observed. Due to the IRI renal
function significantly decreased in all intervention groups by
POD1. Recovery of renal function started immediately thereafter
leading to a continuous decrease of CrS and BUN until POD4.
However, HF-treated rats showed a significantly improved
creatinine-clearance as well as urea-clearance. Furthermore, urine
osmolarity, proteinuria, and polyuria improved significantly as
shown in figure 1 and table 2. To sum up, renal damage was
reduced and kidney function of HF-treated animals recovered
faster than in controls. While kidney function normalized already
on POD2 in NxIRHF (no significant differences compared to
baseline values), kidney function of untreated rats failed to
normalize even 48 h later at least for some parameters.
Effects of HF on histological changes and on 18F-FDG-
uptake in autoradiography
To estimate renal damage and infiltration (also for validation of
18F-FDG data) we evaluated renal histology (Figure 2) in addition
to metabolic parameters. Subsequent to IRI (POD4), kidneys
presented with signs of ATN, i.e. tubular dilation, swelling, and
necrosis, in addition to intraluminal brush border debris and
protein casts. Leukocyte infiltration was moderate and emphasized
in the outer medulla. Corresponding to improved renal function,
kidneys of NxIRHF showed reduced signs of ATN including
attenuated interstitial infiltration when compared with NxIRCTR.
Examination of inflamed tissue by autoradiography has shown
that 18F-FDG-accumulation is correlated to the degree of
inflammatory infiltration in different pathophysiological scenarios
[38,41]. Thus, we amended histological evaluation by autoradio-
graphic assessment of mid-coronary kidney slices in order to
visualize inflamed tissue areas. Exemplary measures are given in
figure 2. In congruence to histological data, we found a distinct
18F-FDG-uptake in the outer medulla region of NxIRCTR with
ATN whereas this was absent in NxIRHF. Both, histologic and
autoradiographic evaluation of kidneys showed distinct ameliora-
tion of renal damage (less structural damage, less inflammation) in
the HF-treated group.
Table 2. Effects of IRI on functional parameters of either vehicle-treated (NxIRCTR) or hydroxyfasudil-treated (NxIRHF) animals.
POD-7 POD0 POD1 POD2 POD3 POD4
NxIRCTR
&
NxIRHF
(n =14)
NxIRCTR
&
NxIRHF
(n =18)
NxIRCTR
(n =8)
NxIRHF
(n =10)
NxIRCTR
(n =6)
NxIRHF
(n =8)
NxIRCTR
(n =6)
NxIRHF
(n =8)
NxIRCTR
(n=8)
NxIRHF
(n=10)
Urine volume
(ml/24 h)
14.08
60.93
17.64
60.88
26.95
62.82*
18.92
61.72
43.6
62.85*
22.03
62.20
30.86
62.16*
18.92
61.24
29.47
62.26*
19.58
60.97
Urine osmolarity
(mmosm/kg)
1909
6120.8
1502
682.01
527.5
678.13*
978
692.30*
536.8
627.13*
1280
6150.0
698.8
653.29*
1328
6117.9
941
6111.1*
1409
686.30
Na+ in serum
(mM)
142.8
61.02
147.7
61.28
146
62.29
146.2
61.19
147.7
60.92
145.3
61.37
146.7
60.95
145.8
61.42
146.3
62.89
143.1
62.14
Na+ in urine
(mM)
102
66.57
84.67
66.33
17.88
63.1*
32.5
68.26*
28
63.01*
71.13
611.64
33.67
65.39*
62.13
68.62
56.88
69.25
91.3
65.97
FENa+
(%)
0.22
60.01
0.38
60.03
0.52
60.18
0.23
60.04
0.62
60.11
0.40
60.06
0.44
60.05
0.32
60.07
0.58
60.06
0.44
60.02
K+ in serum
(mM)
4.99
60.18
4.89
60.1
6.35
60.58
5.44
60.52
5.1
60.18
5.23
60.16
4.92
60.22
5.05
60.33
4.94
60.12
4.82
60.22
K+ in urine
(mM)
276.9
615.31
255.6
612.93
97.45
68.25*
131.5
616.14*
83.67
65.67*
174.7
622.36*
102.8
610.72*
203.3
618.95
149.6
620.96*
225.2
612.76
FEK+
(%)
17.25
60.95
35.74
62.61
80.8
622.95*
26.94
62.75
52.12
611.69
25.91
61.82
41.17
62.63
29.62
63.30
45.8
62.10
32.94
61.65
Proteine excretion
(mg/mg creatinine)
0.31
60.02
0.51
60.03
1.31
60.15*
0.75
60.08
0.96
60.1*
0.59
60.08
0.70
60.03
0.43
60.02
0.87
60.11*
0.44
60.05
Serum creatinine
(Cr, mg/dl)
0.19
60.01
0.35
60.01
1.10
60.19*
0.52
60.06
0.68
60.10*
0.38
60.03
0.51
60.07
0.36
60.03
0.44
60.05
0.34
60.02
Blood urea nitrogen
(BUN, mg/dl)
17.93
60.62
24.17
60.84
62
68.93*
35.2
63.96
53.17
66.96*
27
61.39
43
67.08*
23.25
61.21
36.14
66.46
23
61
CrCl
(ml/min/100 g BW)
0.97
60.05
0.56
60.02
0.14
60.03*
0.38
60.04*
0.35
60.05*
0.55
60.04
0.38
60.03
0.57
60.04
0.43
60.04
0.61
60.04
BUN-Cl
(ml/min/100 g BW)
0.39
60.02
0.29
60.01
0.06
60.01*
0.17
60.02*
0.17
60.03*
0.29
60.02
0.20
60.03
0.33
60.02
0.28
60.04
0.34
60.02
Mean values 6 SEM with the number of animals in parentheses;
*p,0.05 vs. POD0. BW: body weight, POD: postoperative day, FENa+: fractional excretion of Na
+, FEK+: fractional excretion of K
+.
doi:10.1371/journal.pone.0026419.t002
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Effects of HF on ROCK-activity, renal perfusion and
blood-pressure
ROCK-inhibition was verified by evaluating the phosphoryla-
tion status of the ROCK-substrate phospho-MYPT1 by quanti-
tative Western Blot analysis. As depicted in Figure 3D, in NxIRHF
ROCK-activity was significantly reduced in kidney samples taken
immediately before the ischemia procedure (NxIRCTR
0.4660.06 vs. NxIRHF 0.3160.03, n= 7, p,0.05). Additionally,
even though our results indicated a crucial role of ROCK-
dependent leukocyte recruitment in renal IRI so far, the clinical
field of application of ROCK-inhibitors (e.g., Fasudil) lies within
cardiovascular diseases, where mainly vasodilatatory and therefore
blood-pressure lowering effects are observed. Hence, one might
assume that the post-ischemic functional improvement of kidneys
was mediated by increased perfusion (via vasodilatation). To test
this hypothesis, we assessed renal perfusion by 18F-PET and
calculated a modified Hilson’s Perfusion index (Hilson’s PI,
Figure 3, higher values indicate lower perfusion rates). At baseline
renal perfusion did not differ between groups and kidneys (CTR:
148.0612.3, n = 9 vs. HF: 155.7611.2, n= 9). Ischemia led to a
significant decrease of renal perfusion in the affected kidney only
as assessed immediately after the ischemia inducing operation.
Again, there was no difference between NxIRCTR POD0
(192.8625.7, n = 7) and NxIRHF POD0 (197.0615.0, n= 8).
However, on POD4 renal perfusion in vehicle-treated animals was
still impaired while the renal perfusion of HF-treated rats had
completely recovered (NxIRCTR POD4: 186.9614.5, n= 6 vs.
NxIRHF POD4: 152.4611.6, n= 8). In addition, blood-pressure
lowering effects of HF were excluded by use of a non-invasive,
volume pressure recording technique (Figure 3C) which is
consistent with work published by Komers et al. [42].
Effect of ROCK-inhibition on renal endothelial
permeability after IRI
Our results so far indicated a HF-related modulation of the
inflammatory response affecting adhesive and migratory capabil-
ities of immune cells. Additionally, HF-treatment modifies
adhesion molecule expression and renal perfusion in the long
run, which indicates HF-effects on endothelia. Thus, we aimed to
test endothelial functionality by applying an Evans Blue (EB)-
based vascular permeability assay during the initial 30 minutes of
the reperfusion phase (Figure 4). Performing spectrophotometrical
analyses of the renal content of EB after IRI, we assessed a distinct
higher accumulation of EB in untreated (NxIRCTR:
Figure 1. Effects of ischemia-reperfusion injury and ROCK-inhibition on metabolic parameters. IRI significantly affected kidney function
(as assessed by creatinine-clearance, urea-clearance, urine osmolarity and urine protein excretion on POD0-4) whereas the renal function of HF-
treated animals was less severe affected. Starting on POD 1, HF-treated animals had improved creatinine-clearance (NxIRHF: 0.3860.04 ml/min/100 g
vs. NxIRCTR: 0.1460.03 ml/min/100 g, n = 6) as well as urea-clearance (NxIRHF: 0.1760.02 ml/min/100 g vs. NxIRCTR: 0.0660.01 ml/min/100 g, n = 6)
when compared to vehicle-treated rats. Moreover, the HF-treated rats showed a better preserved renal urinary concentrating capacity. Interestingly,
proteinuria, which initially occurred in the NxIRCTR group was absent in NxIRHF. In summary, kidney injury was significantly attenuated by HF
application leading to a distinct faster recovery of renal function. Values are expressed as mean 6 SEM; *indicates significance to NxIRCTR POD0.
doi:10.1371/journal.pone.0026419.g001
ROCK-Inhibition Improves Kidney Function in IRI
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26419
Figure 2. Effect of ischemia-reperfusion injury andROCK-inhibition onhistological changes. Shown are representative PAS-stainings (cortex and
medulla) and 18F-FDG-autoradiographies of post-ischemic kidneys on POD4 (NxIRCTR, NxIRHF), as well as PAS-stainings of kidneys from healthy (CTR) and
uninephrectomized animals (Nx). Following IRI kidneys presented with signs of ATN, i.e. tubular dilation, swelling and necrosis in addition to intraluminal
brush border debris and protein casts. Leukocyte infiltration was moderate and emphasized in the outer medulla. Kidneys of HF-treated animals (NxIRHF)
showed reduced signs of ATN including attenuated interstitial infiltration when compared with vehicle-treated animals (NxIRCTR). In congruence, we found
distinct 18F-FDG-uptake (quantified as counts per second (cps)/mm2) in the outer medulla region of NxIRCTR (arrows in autoradiography) with ATN whereas
this was absent in the NxIRHF group. This was statistically verified by calculating the ratio (E/OM), between the 18F-FDG-uptake in the entire organ slice (E)
compared to that in the outer medulla (OM). While there is no statistical difference between uninephrectomized (Nx: 1.260.02) and ROCK-inhibitor treated
(NxIRHF: 1.1260.04) animals, the E/OM ratio of untreated ischemic animals (NxIRCTR: 0.8860.06) is significantly different from both aforementioned. Values
are expressed as mean 6 SEM, n=3. * p,0.05 vs. Nx & NxIRHF). Non-marked, intensively stained areas are artifacts due to renal 18F-FDG excretion.
doi:10.1371/journal.pone.0026419.g002
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16.761.3 mg/ml, n= 4) than in HF-treated rats (NxIRHF:
12.461.3 mg/ml, n= 5) (* p,0.05 vs. NxIRCTR).
Effects of HF on the expression of matrix
metalloproteinases
In the next step, we aimed to clarify if the infiltrates observed
after IRI were harmful to the kidney. Therefore, we employed
real-time polymerase chain reaction (PCR) and immunohisto-
chemical analyses of matrix metalloproteinases (Mmp). The
mRNA-expression results of Mmp2, Mmp7, Mmp8, and Mmp9
are presented in figure 5A. Whereas upon IRI-treatment, vehicle-
treated animals demonstrated up-regulated levels of Mmp2 and
Mmp7, Mmp9 was down-regulated when compared to HF-treated
animals. Exemplary immunohistochemistry of Mmp2 and Mmp9
confirmed these findings also on the protein-expression level
(Figure 5B and C).
Effects of HF on mRNA-expression analyses of selected
genes
Because ROCK-inhibition considerably improved renal recov-
ery after IRI and reduced inflammation, we aimed to analyze the
expression of possibly involved genes. Although earlier analyses
have linked ROCK-inhibition to reduced infiltration of macro-
phages into the (post-ischemic) kidney [11,12,43] a precise analysis
of the immune cell types, i.e. neutrophiles, monocytes, as well as B-
and T-cells, involved is lacking. Recently, it has been shown that
ROCK-inhibition generally negatively influences the ability of
leukocytes to adhere and to (trans-) migrate [25,26,28,30,32].
Figure 3. Effect of ischemia-reperfusion injury and ROCK-inhibition on renal perfusion. A) Exemplary, representative time activity curve
(TAC) of the arterial bloodpool and of both kidneys in a control rat on POD4. Areas under the curves during the first 30 seconds after 18F-fluoride
injection were used to calculate the perfusion index (perfusion index left kidney: 310.7 (post IR), right kidney: 185.6 (CTR)). B) Comparison of the
modified Hilson’s Perfusion index between the two groups as assessed by 18F-PET. At the beginning of the reperfusion phase (POD0, post-ischemia)
kidney perfusion was significantly impaired in both groups (CTR POD0: 192.8625.7, n = 7 and HF POD0: 197.0615.0, n = 8) compared with baseline
values (CTR: 148.0612.3, n = 9 vs. HF: 155.7611.2, n = 9). However, kidney perfusion of the HF-treated rats has already recovered on POD4 while
perfusion of the vehicle-treated group was still impaired (CTR POD4: 186.9614.5, n = 6 vs. HF POD4: 152.4611.6, n = 8) (1 p, 0.05 vs. baseline,
* p,0.05 HF POD4 vs. CTR POD4). C) Mean systolic and diastolic blood-pressures of conscious rats before ischemia induction on POD0. No significant
differences were detected between HF- and sham-treated animals (NxIRCTR 130.063.6 mmHg (systolic) 92.663.3 mmHg (diastolic), n = 8 vs. NxIRHF
118.864.8 (systolic) 82.764.2 (diastolic) n = 7, p,0.05). D) Relative phospho-MYPT1 expression in relation to GAPDH for HF- and sham treated animals
as assessed by quantitative Western Blot analysis (NxIRCTR 0.4660.06 vs. NxIRHF 0.3160.03, n = 7, p,0.05).
doi:10.1371/journal.pone.0026419.g003
ROCK-Inhibition Improves Kidney Function in IRI
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26419
Moreover, ROCK-inhibition significantly influences the integrity
and permeability of endo- and epithelia. In a first step, we
analyzed marker genes of specific leukocyte subpopulations on
POD1 and POD4 (Figure 6) to characterize the post-ischemic
infiltrate and the effect of HF on different immune cell types. On
POD1 following IRI, there was no significant difference between
the HF treated and untreated IRI rats, besides the mRNA of the
up-regulated B-cell marker CD20 and the neutrophil granulocytes
marker Ceacam1, which was downregulated in the HF group. On
POD4, HF treatment attenuated the up-regulation of Ceacam1,
CD80 (activated B-cells/monocytes), CD86 (antigen presenting
cells and the monocyte/macrophage activity marker ficolin B.
As a second gene set, we measured mRNA-expression of
pro-inflammatory cytokines such as interferon gamma (Infg),
tumor necrosis factor (Tnf), tumor necrosis factor (ligand)
superfamily member 15 (Tnfsf15), adhesion molecules (Icam1,
Vcam1), and kidney injury molecule 1 (Kim1). On POD1, we
assessed a distinct up-regulation of Kim1 only, whereas on POD4
Icam1, Vcam1, and Kim1 were up-regulated. HF, treatment
attenuated the up-regulation of Kim1 (POD1 and 4), Icam1 and
Vcam1 (POD4). However, in the latter case (Vcam1) expression
was only attenuated in NxIRHF when compared to uninephrec-
tomized animals but failed to be significantly downregulated when
compared to NxIRCTR. Ifng, Tnf and Tnfsf15 were not
significantly different expressed on POD1 and 4; Figure 6 and
Figure S1 (for Figure S1 see supplemental data)).
Figure 4. Effect of ischemia-reperfusion injury and ROCK-inhibition on renal vascular permeability. A) Renal vascular permeability as
assessed by Evans Blue (EB) tissue accrual after 30 min of reperfusion in renal sections. Kidney of untreated (NxIRCTR) rats exhibit thereby increased
accumulation of EB compared with HF-treated rats (NxIRHF) as assessed by B) spectrophotometrical quantification at 620 nm (NxIRCTR: 16.761.3 mg/
ml, n = 4, NxIRHF: 12.461,3 mg/ml, n = 5) (* p,0.05 vs. NxIRCTR). C) Evaluation of kidney wet weight/100 g body weight ratio. In comparison with
healthy animals (CTR) kidney weight significantly increased in all groups. However, compared with uninephrectomized animals (Nx) the kidney wet
weight/100 g body weight ratio only increased significantly in untreated ischemic animals (NxIRCTR 30 min & POD4), while there was no significant
increase in the ROCK-inhibitor treated group (CTR: n = 18, Nx: n = 6, NxIRCTR 30 min: n = 7, NxIRHF 30 min: n = 8, NxIRCTR POD4: n= 3, NxIRHF POD4:
n = 3; * = p,0,05 vs. CTR, # p,0,05 vs. Nx).
doi:10.1371/journal.pone.0026419.g004
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Figure 5. Effect of ischemia-reperfusion injury and ROCK-inhibition on matrix metalloproteinases expression. A) The mRNA-
expression of Mmp2, Mmp7, Mmp8 and Mmp9 in whole kidney lysates as analyzed by real-time PCR. In vehicle-treated rats ischemia-reperfusion
injury led to a significantly increased mRNA-expression of Mmp2 and Mmp7 on POD4, as well as decreased mRNA-expression of Mmp9 on POD1 and
POD4 when compared to healthy and HF-treated animals. In turn, mRNA-expression of Mmp2 and Mmp7 of HF-treated animals did not change
significantly compared to healthy animals. Differences in gene-expression were reflected by corresponding protein-expression as shown by
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Discussion
Considering the important role of RhoGTPases in cytoskeletal
reorganization of endothelia and leukocyte migration, we
hypothesized that preventive ROCK-inhibition may improve
renal IRI outcome by reducing cellular infiltration. To test our
hypothesis and to elucidate the mechanisms involved, we used an
animal model of IRI. Thereby, we were able to show that renal
IRI was substantially reduced in animals which received the
ROCK-inhibitor HF. Renal function recovered earlier and
inflammation was distinctly lower in HF-treated rats suggesting a
critical role of ROCK in the development of (renal) IRI. We
herein show that several mechanisms contributed to the observed
ROCK-dependent IRI changes, including changes in the
expression of endothelial adhesion molecules, matrix metallopro-
teinases and increased endothelial leakage/vascular permeability
accompanied by leukocyte recruitment and transmigration.
Reviewing the literature this is the first in vivo study showing that
HF-mediated ROCK-inhibition not only improves IRI-induced
tubular damage as illustrated on the cellular and subcellular level
but that it also improves kidney function (former studies used other
ROCK-inhibitors [43–46]). Phenotypical implications of ROCK-
inhibition include improved renal function and reduced leukocyte
recruitment into the post-ischemic kidney. Morphological signs of
IRI in kidneys of untreated animals included signs of severe acute
tubular necrosis such as tubular dilation, swelling, and necrosis in
addition to intra luminal brush border debris and protein casts.
Leukocyte infiltration was moderate and emphasized in the outer
medulla. This corresponded with an increased accumulation of
18F-FDG, as assessed by autoradiography, indicating elevated
metabolic rates due to inflammatory infiltration in these areas
[38,41]. In addition, mRNA-expression levels of Mmp2 and
Mmp7, which are major regulators of extracellular matrix
degradation/turnover, and are therefore critical for tissue
homeostasis [47] increased after IRI in kidneys of untreated
animals, while mRNA-expression of Mmp9 decreased. Changes in
mRNA-levels were reflected by corresponding alterations in
protein-expressions (e.g. Mmp2 and Mmp9). Both, increased
expressions of Mmp2 as well as decreased expression of Mmp9
have been described to promote kidney injury [48,49]. Consistent
with the relation of mRNA-expression of Mmp2 and Mmp7 to the
degree of infiltrating cells (activated leukocytes produce high
amounts of Mmps [50]), levels of Mmp2 and 7 increased in
kidneys of untreated animals which underwent IRI and presented
inflammatory infiltration. ROCK-inhibition by HF negated both,
increased expression of Mmp2 and Mmp7, as well as downreg-
ulation of Mmp9. This hints towards a lower degree of IR-related
tissue damage/inflammation in HF-treated animals. Among
others, these results indicated that leukocytes might play a crucial
role in how ROCK-inhibition affects the development of IRI,
especially in the early stages. Interestingly, it has been shown in
mice that knockout of ROCK1 significantly reduces leukocyte
recruitment and neointima formation following vascular injury
[51]. However, even though some studies claim that kidney
infiltration with macrophages seems to be decreased by ROCK-
inhibition [11,12,43], a comprehensive analysis of immune cell
types involved is lacking. Thus, we used RT-PCR analysis to
confirm and characterize the pattern of inflammatory cells and
to identify ROCK-dependent changes therein. By analyses of
marker genes of leukocyte subpopulations, we observed in
untreated post-ischemic kidneys a distinct up-regulation of marker
mRNA of B-cells (CD20), neutrophil granulocytes (CD66a),
activated B-cells/monocytes (CD80/B7-1), antigen presenting
cells (CD86) and the monocyte/macrophage activity marker
ficolin B (Fcnb). While CD66a and CD20 were already up-
regulated on POD1, we detected increased expression of the other
marker genes only on POD4. This is in congruence to Li et al. who
showed that neutrophils are the spearhead cell type in IRI [52,53].
However, some IRI studies performed with neutrophil-depleted
animals failed to show a protective effect on renal IRI compared
with controls [1,54]. Similarly, it is well known that IRI occurs also
in neutropenic patients [55]. Thus, leukocytes others than
neutrophils seem to be involved as well. Therefore, among others
Takada et al. stated that mononuclear leukocytes may be the main
effector cells involved in IRI [56,57]. Nevertheless, ROCK-
inhibition significantly prevented an up-regulation of all men-
tioned marker genes including neutrophils, B7-1, and mononu-
clear cells in kidney tissue following IR. These findings indicate
that ROCK-activity substantially participates in IRI via modula-
tion of leukocyte infiltration. Consistent with this, it was shown
that ROCK is important for migration of leukocytes [25–32]. The
importance of cell migration for inflammatory responses was
supported recently [33]. Inhibition of the motor protein non-
muscle myosin II which impairs the actinomyosin powered
locomotive machinery improves the progression of experimental
obstructive nephropathy which serves as a model of progressive
renal disease mainly by its potent anti-inflammatory effect [58]. In
a model of hypertensive nephropathy inhibition of lymphocyte
migration limited histological and molecular fibrosis without
affecting increased systemic blood-pressure [59]. As immune cell
migration depends on endothelial adhesion molecules and as
neutrophils are capable of producing a variety of hyperperme-
ability factors, e.g. cytokines which directly or indirectly interact
with the endothelium, we analyzed a second gene set including
pro-inflammatory cytokines (Ifng, Tnf, Tnfsf15) and adhesion
molecules (Icam1, Vcam1). While IRI caused a distinct up-
regulation in the mRNA expression levels of Icam1, Vcam1 and,
especially, in the case of Kim1 (which serves as an indicator of
kidney injury [60]), ROCK-inhibition led to significantly lower
expression levels of Icam1 and Kim1 while Vcam1 expression was
not significantly attenuated. Since protein data might vary from
gene expression analysis, PCR data might serve as indicator only.
However, mRNA data might indicate that ROCK-inhibition not
only affects the migration capability of leukocytes but also the
capacity of the endothelium to interact with them (lower level of
Icam1). ROCK is a known mediator of apoptosis as it is activated
by caspases [61]. However, in our IRI model there was no
difference in TUNEL staining on post-ischemic day one between
HF-treated animals and controls (Figure S2, supplemental data).
Since apoptosis was significantly attenuated in HF-treated animals
on day four, we hypothesize that attenuation of apoptosis might
rather be secondary to the inhibitory effect of HF on inflammation
(as evidenced e.g. by reduced infiltration in histology and 18F-
FDG-accumulation in the outer medulla). Since functional data
implicate an improvement of kidney function as shown for
example by creatinine clearance as early as day one we assume
that inhibition of apoptosis is not primarily involved in the
beneficial effects of ROCK-inhibition by HF. However, inhibition
of apoptosis could at least in part contribute to the effects
observed.
immunohistochemistry of Mmp2 (B) and Mmp9 (C). Values are expressed as mean 6 SEM, n = 4–5. a p,0.05 vs. CTR, b p,0.05 vs. NxIRCTR POD1,
c p,0.05 vs. CTR and NxIRCTR POD1, d p,0.05 vs. NxIRCTR POD4, e p,0.05 vs. CTR and NxIRCTR POD4.
doi:10.1371/journal.pone.0026419.g005
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The clinical field of application of ROCK-inhibitors (e.g. Fasudil)
lies within cardiovascular diseases, where mainly vasodilatory and
therefore blood-pressure lowering effects of ROCK-inhibitors are
contemplated manner. As tonic modulation of renal arterioles and
the descending vasa recta contributes to the regulation of oxygen
supply and medullary blood-flow [62], one of our hypotheses was
Figure 6. Effect of ischemia-reperfusion injury and ROCK-inhibition on mRNA-expression. Fold change in mRNA-expression compared to
uninephrectomized animals (whole kidney lysates) as analyzed by real-time PCR (CD4, CD8a, CD20/Ms4a1, CD25/Il2ra, CD56/Ncam1, CD66a/Ceacam1,
Fcnb, Foxp3, CD80, CD86, Kim1, Icam1, Vcam1) on POD1 (A) and POD4 (B). Following IRI, we observed a distinct up-regulation of marker mRNA, B-
cells (CD20), neutrophil granulocytes (CD66a), activated B-cells/monocytes (CD80), antigen presenting cells (CD86) and the monocyte/macrophage
activity marker ficolin B (Fcnb). IRI also led to a distinct up-regulation of mRNA-levels of vascular adhesion molecules (Icam1, Vcam1) and, especially,
of Kim1. ROCK-inhibition significantly attenuated the up-regulation of CD66a, CD80, CD86, FcnB, Icam1, Vcam1 and Kim1. CD86 and Vcam1 were not
significantly different in NxIRCTR and NxIRHF. Values are expressed as mean6 SEM, n = 4–6. a p,0.05 vs. Nx, b p,0.05 vs. NxIRCTR POD1 or NxIRCTR
POD4, respectively.
doi:10.1371/journal.pone.0026419.g006
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that HF-related renal protection from IRI is related to vasodilata-
tion resulting in improved kidney perfusion immediately after
ischemia induction.
To elucidate this hypothesis, we non-invasively measured
animal blood-pressures before surgery as well as renal perfusion
by 18F-PET after surgery and calculated a modified Hilson’s
Perfusion index. Notably, renal perfusion did neither differ
between groups at baseline measurements nor immediately after
the ischemia procedure. Blood-pressure was not affected, too.
Thus, in IRI acute vasodilatory effects of HF are not decisive for
kidney protection. However, while renal perfusion in vehicle-
treated animals was still impaired on POD4, renal perfusion of
HF-treated rats had completely recovered. The reduced perfusion
of vehicle-treated kidneys might be related to an increased
endothelial permeability leading to interstitial edema (higher
kidney weights in the NxIRCTR group) compressing the
peritubular capillaries, to increased leukocyte adherence, and the
extravascular accumulation of leukocytes [62]. ROCKs are central
to cell-cell contacts, to cellular contraction and therefore to
endothelial barrier function. Interestingly, the integrity of the
endothelium is distinctly compromised in IRI, leading to
extravasation of leukocytes and interstitial edema. As we observed
more edema in kidneys of control animals than in HF-treated
ones, we tested the endothelial barrier function/permeability in
vivo in the first 30 minutes of the reperfusion phase. Notably, dye-
accumulation was significantly reduced when ROCK-inhibition
was applied indicating preserved endothelial function and integrity
after IRI. This view is supported by data obtained in a model of
ischemic stroke in mice. Ischemia of the middle cerebral artery
induced endothelial contraction and disruption of the blood brain
barrier with increased permeability that was prevented by ROCK-
inhibition [63]. Since leukocyte transmigration depends on trans-
endothelial migration, increased tightness of the endothelium is
likely to result in reduced migration and infiltration. This
decreases inflammation of the kidney. Therefore, the data suggests
that improved kidney function after ROCK-inhibition was mainly
mediated by affecting the inflammatory response and reducing
edema compressing the peritubular capillaries. On one hand,
migratory and adhesive capabilities of leukocytes were substan-
tially reduced, either by direct effects or through the endothelium
by affecting endothelial adhesion molecules and endothelial
permeability. On the other hand, possible direct effects of HF
on renal perfusion due to ROCK-inhibition related vasodilatation
could be excluded.
We conclude from our study that ROCK-inhibition by HF
significantly improves kidney function in a rat model of acute renal
IRI. This was related to preserved endothelial function and lower
expression of vascular adhesion molecules resulting in reduced/
modulated infiltration and activity of tissue destructing Mmps, less
edema and better perfusion. Therefore, ROCK-inhibition is a
promising potential therapeutic target in renal IRI.
Supporting Information
Figure S1 Effect of ischemia-reperfusion injury and
ROCK-inhibition on mRNA-expression. Fold change in
mRNA-expression compared to uninephrectomized animals
(whole kidney lysates) of pro-inflammatory cytokines (Ifng, Tnf,
Tnfsf15) on POD1 and POD4. As analyzed by real-time PCR, IRI
did not lead to a distinct up-regulation of these gene transcripts,
neither in the ischemic control group (NxIRCTR), nor in the
ROCK-inhibitor treated animals (NxIRHF). Values are expressed
as mean 6 SEM, n= 4–6. a p,0.05 vs. Nx, b p,0.05 vs.
NxIRCTR POD1 or NxIRCTR POD4, respectively.
(TIF)
Figure S2 Effects of ROCK-inhibition on ischemia-
reperfusion injury-induced apoptosis. A) Representative
TUNEL-stainings (cortex and medulla) of post-ischemic kidneys
on POD1 and POD4 (NxIRCTR, NxIRHF), as well as from
kidneys of healthy (CTR) and uninephrectomized animals (Nx).
On POD1 there was only a slightly increased frequency of
TUNEL-positive nuclei in the untreated ischemic animals
(NxIRCTR) as well as in ROCK-inhibitor treated ones (NxIRHF).
However, on POD 4 kidneys of NxIRCTR animals presented
increased numbers of TUNEL-positive nuclei, whereas kidneys of
ROCK-inhibitor-treated animals (NxIRHF) showed less TUNEL-
positive stainings. B) Quantification of TUNEL-positive nuclei
(#/a.u.): CTR: 562, Nx: 261; NxIRCTR POD1: 32612,
NxIRHF POD1: 35632, NxIRCTR POD4: 2396114, NxIRHF
POD4: 62624. Values are expressed as mean 6 SEM, n=3; *
p,0.05 vs. Nx.
(TIF)
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